- Abbott gets rights to Reata's Phase II bardoxolone
- Kyowa gains Asian rights to bardoxolone from Reata
- AZ pays $100mm up front for rights to Rigel's RA candidate; rights later returned
- AZ pays $200mm up front for rights to Targacept's TC5214; deal terminated
- AZ gets rights to two of Nektar's candidates
- Genzyme and Isis enter $1.2bn CV collaboration
- Pfizer gains rights to Medivation's Dimebon; deal terminated
- BMS, Pfizer work together on Phase III antithrombotic
- GSK gets late-stage cancer/RA antibody from Genmab; transferred to Novartis
- Reata brings in $17mm so far via its Series G round; adds $61mm
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.